GBS Settlement Amounts: What Vaccine Injury Cases Are Really Worth
How much is a Guillain-Barré Syndrome (GBS) vaccine case worth? Learn how pain and suffering is evaluated and what increases compensation.
If you or a loved one has been diagnosed with Guillain-Barré Syndrome (“GBS”) after a vaccine, one of the first questions is: what is the case worth?
There is no fixed answer. Vaccine cases are highly fact-specific, and compensation depends on several categories of damages.
Every case includes compensation for pain and suffering. Some cases also include lost wages, medical expenses, and in more serious situations, future medical care.
Pain and suffering receives the most attention in case law not because it is the most important category, but because it is the only category present in every case. As a result, it provides the most consistent framework for evaluating value across different types of GBS claims. Vaccine injury cases are bifurcated, meaning that causation (did the vaccine cause GBS) must be determined before damages can be awarded.
To assess whether a vaccine caused GBS, click here.
How Pain and Suffering Is Evaluated in GBS Cases
Pain and suffering is capped at $250,000 under the Vaccine Act, but within that cap there is no formula, only guidance from the Vaccine Court decisions. The Court evaluates severity, duration, and long-term impact, and then compares those facts to prior cases.
That comparison process is critical. GBS exists on a spectrum—from relatively mild cases with strong recovery to catastrophic cases involving respiratory failure, long-term disability, or death. Understanding where a case falls on that spectrum is what determines value.
The Floor: Strong Recovery, Limited Residual Symptoms
At the lower end of the range are cases where GBS is serious but ultimately resolves with relatively limited long-term impact.
These cases still involve real suffering. Individuals often experience rapid onset of neurological symptoms, including weakness, numbness, and difficulty walking. There may be a period of significant functional limitation, and in many instances, individuals seek emergency care or short-term hospitalization. However, these cases are defined by what happens after the acute phase.
In floor-level cases, recovery is steady and meaningful. The individual regains independence, returns to work, and resumes most daily activities. Residual symptoms may remain—such as intermittent numbness, tingling, or fatigue—but they are manageable and do not fundamentally alter the person’s lifestyle.
The Court has recognized that even these cases warrant substantial compensation because GBS is inherently serious and frightening. But where there is no prolonged hospitalization, no respiratory involvement, and no lasting functional impairment, pain and suffering awards tend to fall in the $130,000 to $150,000 range.
What distinguishes these cases is not the absence of suffering—it is the absence of long-term disruption.
Mid to Upper Range: Severe Acute Course With Lasting Effects
Most GBS cases fall into a middle-to-upper range where the illness is significantly more severe and the recovery is incomplete.
These cases typically involve a clear and dramatic progression. Symptoms begin with tingling or weakness and rapidly escalate to the point where the individual cannot walk, cannot perform basic activities, and requires hospitalization. Treatment often includes IVIG or plasmapheresis, and many individuals require extended inpatient care followed by weeks or months of rehabilitation.
What drives value in these cases is not just the acute illness, but the length and intensity of the recovery. Individuals are often discharged from the hospital but are far from recovered. They may require assistive devices such as walkers or braces. They may struggle with coordination, balance, and endurance. Even after formal therapy ends, symptoms frequently persist.
The case reflected in illustrates this category well. There, the individual experienced rapid onset of weakness and neurological symptoms within weeks of vaccination, followed by hospitalization, IVIG treatment, and an extended inpatient rehabilitation course. He was unable to walk, required significant assistance for daily activities, and underwent multiple transfers between facilities before gradually improving. Even after returning home, he continued to experience neuropathic pain, weakness, and coordination issues that affected his daily life and ability to work.
Similarly, in another case, the individual’s condition progressed to respiratory complications, prolonged hospitalization, and an extended recovery marked by persistent weakness and functional limitations. That case resulted in a pain and suffering award of $200,000, reflecting both the severity of the acute illness and the lasting impact of the condition .
These cases tend to fall in the $175,000 to $200,000 range, and what separates them from lower-end cases is clear: prolonged disability, aggressive treatment, and persistent symptoms that meaningfully affect daily life.
Upper Range With Future Care: When GBS Does Not Fully Resolve
At the highest end of non-death cases are those where GBS results in lasting, life-altering impairment.
In these cases, the individual does not return to a functional baseline. Instead, they may continue to experience significant weakness, impaired mobility, chronic fatigue, and neurological deficits that affect nearly every aspect of daily living. Walking may remain difficult or unsafe. Employment may no longer be possible. Independence may be limited.
What distinguishes these cases is the need for ongoing care.
Unlike moderate cases where treatment eventually ends, these cases often require long-term medical management. This is where future medical care becomes a critical component of compensation. A life care planner or nursing expert is typically retained to evaluate the individual’s condition, consult with treating providers, and develop a detailed plan outlining future needs. That plan may include ongoing therapy, medications, assistive devices, home modifications, and in some cases, in-home care.
The Vaccine Program is designed to cover these future costs, often through structured or annual payments.
In these cases, pain and suffering often approaches the $250,000 cap because of the severity and permanence of the condition. But the overall value of the case increases significantly because of the addition of future care costs.
The key distinction is that these cases are no longer defined by recovery—they are defined by permanence.
Death Cases: The Most Severe Outcomes
At the far end of the spectrum are cases where GBS results in death.
These cases often involve a rapid and devastating clinical course. Individuals may present with progressive weakness that quickly escalates to respiratory failure. Many require intubation, mechanical ventilation, and intensive care. Complications such as infections, autonomic instability, or cardiac events can follow.
The suffering in these cases is profound. Individuals often endure severe physical pain, total loss of independence, and the psychological distress associated with a rapidly deteriorating condition.
The case reflected in demonstrates this trajectory. There, the individual experienced rapid onset of weakness that progressed to quadriplegia and respiratory failure. She required intubation, tracheostomy, and feeding tube placement, along with aggressive inpatient care and rehabilitation. Despite these interventions, her condition continued to decline, leading to prolonged institutional care and ultimately death following complications related to her GBS.
In death cases, compensation includes both the individual’s pain and suffering prior to death and a statutory $250,000 death benefit. In one such case, the Court awarded $200,000 for pain and suffering along with the $250,000 death benefit, reflecting both the severity of the illness and the suffering endured before death .
These cases represent the most severe outcomes, where the illness not only disrupts life but ultimately ends it.
What Actually Increases the Value of a GBS Case
Across all categories, the same core factors drive value: the severity of the illness, the length of recovery, and the extent of lasting impact.
Pain and suffering provides the baseline because it exists in every case. From there, value increases when the evidence shows prolonged hospitalization, aggressive treatment, lasting symptoms, inability to return to baseline function, and, in the most serious cases, the need for ongoing care or the occurrence of death.
Lost wages and medical expenses can further increase value, but they are secondary to the overall clinical picture.
Final Thoughts: Understanding Where a Case Falls on the Spectrum
GBS cases are best understood as existing on a spectrum.
At one end are cases with strong recovery and limited long-term impact. At the other end are cases involving permanent disability or death. Most cases fall somewhere in between, where the illness is severe and recovery is incomplete.
The value of a case depends on where it falls along that spectrum.
Pain and suffering serves as the foundation because it reflects what every individual endures. Additional damages build on that foundation depending on how significantly the condition affects the person’s life.
Understanding that framework is the key to understanding how GBS cases are evaluated—and what they are worth.
Key Resources to Understand the Vaccine Court, How a Case Progresses, and GBS cases, see below: